Dojelitowa postać lewodopy w leczeniu zaawansowanej choroby Parkinsona

Neurologia i Neurochirurgia Polska

Volumn 44, Issue 4, 2010, Pages 396-403

  Sławek, Jarosław ^a,b   Bogucki, Andrzej ^c,d  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Oddzial Neurologii   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d Kliniczny Oddzia Neurologii   (Poland)

Author keywords

Duodopa system; Dyskinesias; Fluctuations; Parkinson disease

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DUODENUM; DYSKINESIA, DRUG-INDUCED; HUMAN; INFUSION PUMP; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; CARBIDOPA; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DUODENUM; DYSKINESIA, DRUG-INDUCED; HUMANS; INFUSION PUMPS; LEVODOPA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77956916144     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3843(14)60299-1     Document Type: Review

References (24)

1. Rinne U.K. Problems associated with long-term levodopa treatment of Parkinson's Disease. Acta Neurol Scand Suppl 1983; 95: 19-26.
2. Markhan C.H., Diamond S.G. Long term follow up of early dopa treatment in Parkinson's Disease. Ann Neurol 1986; 19: 365-372.
3. Nyholm D., Askmark H., Gomes-Trolin C. i wsp. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-163.
4. Jost W., Baas H., Csoti I. i wsp. The treatment of advanced Parkinson's Disease. UNI-MED Science, Bremen 2008, ss. 60-62.
5. Quinn N., Marsden C.D., Parkes J.D. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982; 2: 412-415.
6. Kurth M.C., Tetrud J.W., Tanner C.M. i wsp. Double-blind, placebo controlled cross-over study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43: 1698-1703.
7. Nyholm D., Aquilonius S.M. Levodopa infusion therapy in Parkinson disease. Clin Neuropharmacol 2004; 27: 245-256.
8. Nyholm D., Jansson R., Willows T. i wsp. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005; 65: 1506-1507.
9. Eggert K., Schrader C., Hahn M. i wsp. Continuous jejunal levodopa infusion in patients with advanced Parkinson's disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008; 31: 151-166.
10. Danish and Swedish Movement Disorders Societes. Duodopa Scandinavian Consensus; dostȩpne na: www.swemodis.se.
11. Devos D.; French DUODOPA Study Group. Patient's profile, indications, efficacy and safety of levodopa duodenal infusion in advanced Parkinson's Disease. Mov Disord 2009; 24: 993-1000.
12. Sławek J. Zabiegi stereotaktyczne w chorobie Parkinsona - zasady kwalifikacji chorych w oewietle dotychczasowych badañ. Neurol Neurochir Pol 2003; 37: 215-227.
13. Friedman A., Harat M., Opala G. i wsp. Konsensus w zakresie wskazañ do leczenia operacyjnego choroby Parkinsona. Neurol Neurochir Pol 2003; 37 (supl. 5): 11-17.
14. Antonini A., Isaias I.U., Canesi M. i wsp. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149.
15. Nyholm D., Lewander T., Johansson A. i wsp. Enteral levodopa/carbidopa infusion in advanced Parkinson's disease: long-term exposure. Clin Neuropharmacol 2008; 31: 63-73.
16. Odin P., Rüssmann A., Aquilonis S.-M. Pump-driven continuous duodenal administration of levodopa. A new therapy for patients with advanced Parkinson's disease. Psychopharmakotherapie 2005; 12: 1-5.
17. Nyholm D., Nilsson Remahl A.I., Dizdar N. i wsp. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
18. Dewey R.B. Jr, Hutton J.T., LeWitt P.A. i wsp. A randomized, double-blind, placebo-controlled trial on subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385-1392.
19. Nyholm D., Constantinescu R., Holmberg B. i wsp. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009; 119: 345-348.
20. Defer G.L., Widner H., Marié R.M. i wsp. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-584.
21. Morgante L., Morgante F., Moro E. i wsp. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus. Results of a questionnaire. Parkinsonism Relat Disord 2007; 13: 528-531.
22. Volkmann J. Deep brain stimulation or duodenal levodopa/carbidopa infusion. Choosing the right therapy for individual patients. CNS Spectr 2008; 13 (supl. 7): 8-10.
23. Block G., Liss C., Reines S. i wsp. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23-27.
24. Hauser S.A., Panisset M., Abruzzesse G. i wsp. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009; 24: 541-550.